3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
5
Oxaliplatin
4
durvalumab
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Fluorouracil
3
tivozanib
2
Specimen Handling
2
Capecitabine
2
zimberelimab
1
trametinib
1
tislelizumab
1
quemliclustat
1
pertuzumab
1
olaparib
1
irinotecan sucrosofate
1
atezolizumab
1
anlotinib
1
Yttrium-90
1
Tissue Adhesives
1
Tegafur
1
Stents
1
S 1 (combination)
1
Ritonavir
1
Radiosurgery
1
Pancreaticojejunostomy
1
Pancreaticoduodenectomy
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
No trials found.